AC Immune SA reported first‑quarter 2026 results, posting a net loss of CHF 14.8 million and contract revenue of CHF 1.1 million for the period ended March 31, 2026. The loss per share was CHF 0.15, a slight improvement over the CHF 0.19 loss reported in the prior quarter.
The revenue beat analyst expectations of roughly CHF 0.33 million, driven by stronger contract activity in the company’s Alzheimer’s and Parkinson’s disease programs. The beat reflects the company’s ability to generate cash from its collaborations while continuing to invest heavily in research and development.
Compared with the same period a year earlier, the net loss narrowed from CHF 19.0 million to CHF 14.8 million, and revenue rose from CHF 0.99 million to CHF 1.1 million. The improvement is largely attributable to disciplined cost management, with R&D expenses falling to CHF 11.8 million and G&A expenses remaining stable at CHF 4.2 million.
AC Immune’s cash balance stood at CHF 74.8 million as of March 31, 2026, giving the company a runway into the fourth quarter of 2027 even before potential milestone payments from its Takeda and Eli Lilly collaborations. The company’s leadership highlighted progress in its NLRP3 inhibitor and alpha‑synuclein immunotherapy programs, underscoring the strategic importance of its pipeline to future revenue growth.
While the company did not provide new guidance for the remainder of 2026, the results suggest a continued focus on cost discipline and pipeline development, positioning AC Immune to capitalize on upcoming data readouts and potential partnership milestones.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.